RANDOMIZED COMPARISON OF CIRCUMFERENTIAL PULMONARY VEIN ABLATION VERSUS ANTIARRHYTHMIC THERAPY FOR CURING PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION. (APAF STUDY)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-004337-33-IT

Enrollment

Unknown

Registered

2005-03-02

Start date

2004-11-12

Completion date

Unknown

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

APPLICATION OF CIRCUMFERENTIAL PULMONARY VEIN ABLATION IN THE TREATMENT OF PAROXYSMAL ATRIAL FIBRILLATION MedDRA version: 6.1 Level: SOC Classification code 10007541

Interventions

Trade Name: ALMARYTM*100MG 20CPR Product Name: NA Product Code: NA Pharmaceutical Form: Tablet INN or Proposed INN: Flecainide CAS Number: 54143-56-5 Concentration unit: mg milligram(s) Concentration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026